Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Join | Sign in
Home>Resources>Posters

  Posters

Novel Gpr39 Agonists: Correlation Of Binding Affinity Using Label-Free Back-Scattering Interferometry With Potency In Functional Assays
Daniel Brown (1), Niklas Larsson (2), Ola Fjellström (3), Anders Johansson (3), Sara Lundqvist (2), Johan Brengdahl (2), and Richard J. Isaacs (1)

We describe the application of back-scattering interferometry (BSI) to the characterization of small molecule ligand binding to human GPR39 (a GPCR targeted for type-2 diabetes therapy) overexpressed in crude membrane fractions in free solution, including how BSI-derived affinity and functional assay-derived potency correlate for compounds of varying scaffolds.

Rapid Quantification of Proteins in Complex Matrices using the DeNovix DS11 Microvolume Spectrophotometer
Mebs A Surve & Dan Schieffer

In this poster, we will introduce the DeNovix DS-11 as the next generation in microvolume spectrophotometry.

Mixtures Analysis of Complex Mixtures
Michael Bernstein; Carlos Cobas; Santi Domínguez; Manuel Pérez; Agustín Barba

We describe an NMR method to quantify mixture components in wine, edible oils, etc. The method is fully customizable, and amenable to high throughput operation.

A Complete Wine Analysis Using Multiplets Detection
Dr Michael Bernstein1; Agustín Barba1; Dr Susanne Klein2; Dr Andrea Dreiseitel2; Daniel Heidger2 and Volker Heidger2

NMR mixtures analysis can be used to determine the concentration of key components in wine. Here we show the analysis using SMA from Mestrelab.

Novel Gpr39 Agonists: Correlation Of Binding Affinity Using Label-Free Back-Scattering Interferometry With Potency In Functional Assays
Daniel Brown (1), Niklas Larsson (2), Ola Fjellström (3), Anders Johansson (3), Sara Lundqvist (2), Johan Brengdahl (2), and Richard J. Isaacs (1)

We describe the application of back-scattering interferometry (BSI) to the characterization of small molecule ligand binding to human GPR39 (a GPCR targeted for type-2 diabetes therapy) overexpressed in crude membrane fractions in free solution, including how BSI-derived affinity and functional assay-derived potency correlate for compounds of varying scaffolds

MAB Discovery Technology: A Smart Way to Highly Diverse and Functional Therapeutic Antibodies
Hans-Willi Krell

MAB Discovery GmbH developped a highly integrated process which provides diverse antibodies by starting with a high number of B cells and filtering the relevant antibodies by an early-on functional screening.

PRESEPSIN, A SOLUBLE CD14-SUBTYPE, A POSSIBLE NEW BIOMARKER INCREASES IN SEPTIC PATIENTS’ PLASMA FROM PEDIATRIC DEPARTMENT.
Hayato YAMAGUCHI1), Satoshi KIMURA1), Seiji FUKUOKA1), Emiko NAKAMA1), Hideyasu OTO2), Makoto INOUE2), Takashi SOGA2), Shigetaka KITAZAWA2), Yoh UMEDA2)

Increased plasma concentration of soluble CD14-subtype (presepsin) was observed in pediatric patients with bacteremia. Presepsin could be a possible biomarker of sepsis in pediatric patients, however, their reference interval in children could be lower than that of adults. More studies with larger number of samples are required to confirm the result.

A Novel Approach Toward Microfluidic Drug Metabolite Synthesis – Electrosynthetic Methodology Simulating Cytochrome (CYP450) Oxidation
Romain Stalder, Gregory P. Roth and Philip Podmore

A novel microfluidic technology and electrochemical synthesis method is demonstrated for the efficient generation of known drug metabolites. These metabolites are typically generated on first pass hepatic oxidation in vivo. The FLUX Module, a new microfluidic electrochemical cell manufactured by Syrris Ltd., has been employed to generate the metabolites of five commercial drugs: Tolbutamide, Chlorpromazine, Diclofenac, Primidone and Albendazole.

Exploring the Therapeutic Potential of a Peptide Derived from a Poxviral Immune Evasion Protein
Dylan Lawless

•9R-VIPER is an effective at TLR4 and TLR2 signal inhibition than VIPER.
•The structure of 9R-VIPER and the mutant peptide L6AE10A were investigated by NMR.
•Important structural information was uncovered and an explanation was found for the loss
of activity when important residues are changed.

<< 4 5 6 7 8 9 10 >>
Showing Results 61 - 70 of 296
Scientific News
Blood Test Could Help Bowel Cancer Patients Avoid Drug Side-Effects
Manchester researchers have provided early evidence to suggest that a blood test could be used to identify bowel cancer patients that may benefit from more intensive chemotherapy.
Link Between Genetic Variation And Alcohol Dependence
The discovery could help scientists develop more effective drugs to combat alcoholism.
Comparing The Genomes Of The Leprosy Bacteria
EPFL scientists have compared for the first time the genomes of the two bacteria species that cause leprosy. The study shows how the two species evolved from a common ancestor 13.9 million years ago, and offers new insights into their biology that could lead to new treatments.
Bright New Hope for Beating Deadly Hereditary Stomach and Breast Cancers
Researchers use genomic screening to search for vulnerabilities in the cancer cells.
Los Alamos Creates Bioinformatics Tool for Metagenome Analysis
‘GOTTCHA’ tool could aid ID of co-infections in medical samples.
Genetics Help Predict Heart Disease Risk, Statin Benefits
Researchers found that a set of genetic variants could identify people at risk for coronary heart disease and who would benefit most from statin therapy.
New Gene Influences Apple or Pear Shape, Risk of Future Disease
Duke researchers have discovered that a gene called Plexin D1 controls both where fat is stored and how fat cells are shaped.
New Test To Revolutionise Disease Detection In People, Crops And Stock
A single-drop DNA test invented by UQ scientists could revolutionise the detection of diseases in humans, livestock and crops.
New Cyclotron Facility at UT Southwestern
Expands research opportunities and imaging capabilities for detecting, tracking cancer.
Genomic Evolution Of High-Risk Leukemia Traced
Highly sensitive genomic analysis of acute lymphoblastic leukemia cells reveals for the first time how the malignant cells evolve to cause relapse.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters